J. Safra Sarasin Holding AG Acquires 13,235 Shares of Revolution Medicines, Inc. $RVMD

J. Safra Sarasin Holding AG increased its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 170.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,001 shares of the company’s stock after buying an additional 13,235 shares during the period. J. Safra Sarasin Holding AG’s holdings in Revolution Medicines were worth $2,042,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co acquired a new position in shares of Revolution Medicines during the fourth quarter worth approximately $32,000. Global Retirement Partners LLC increased its holdings in shares of Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares in the last quarter. Torren Management LLC bought a new position in Revolution Medicines in the 4th quarter worth approximately $33,000. Arax Advisory Partners bought a new position in Revolution Medicines in the 4th quarter worth approximately $38,000. Finally, Darwin Wealth Management LLC acquired a new position in Revolution Medicines during the 4th quarter worth $40,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $183.95 on Tuesday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a 12-month low of $34.00 and a 12-month high of $193.82. The company has a market capitalization of $39.11 billion, a PE ratio of -26.02 and a beta of 1.37. The firm’s 50 day moving average is $162.03 and its 200-day moving average is $125.51.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the business posted ($1.13) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -7.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Oppenheimer upped their price target on Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $195.00 price target on shares of Revolution Medicines in a report on Monday, July 6th. Wedbush raised their price target on Revolution Medicines from $165.00 to $181.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Finally, Truist Financial lifted their price objective on Revolution Medicines from $179.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Revolution Medicines presently has an average rating of “Moderate Buy” and an average price target of $144.00.

Insider Activity

In other news, COO Margaret A. Horn sold 29,600 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total transaction of $4,739,552.00. Following the completion of the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at $24,762,077.64. This represents a 16.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 252,497 shares of company stock worth $39,481,286. 7.60% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.